Liver senolytics, muscle lipids and AMPK
A phase-2 MASH fibrosis signal, a cardiolipin recovery path, and direct AMPK lifespan gains.
The latest worthwhile longevity and health news, checked for evidence and explained without the hype. No daily noise. No miracle claims.
The archive
Every published issue stays here, free to open and easy to share. Start with the latest issue below.
A phase-2 MASH fibrosis signal, a cardiolipin recovery path, and direct AMPK lifespan gains.
A blood proxy for senescence burden, an oral bacterium linked to slower aging, and a shared sleep path.
A middle-age trial, a faster path to test longevity drugs, and many healthy eating patterns.
Three September papers on ageing blood markers, organ clocks, and sleep-wave integrity.
Plus a frailty trial, Bhutan's rabies milestone and an Lp(a) outcome miss.
Plus why a refill is not adherence, and what a retraction changes.
Why responsive ageing clocks are signals rather than health verdicts, plus an Alzheimer blood panel and a null stroke-care trial.
What 52-week results add to a peer-reviewed oral GLP-1 study, plus tissue ageing, shelf-stable plasma and the Result Ladder.
Our filter
Papers, registries, regulators and guidelines verify the claim, not social posts or press-release excitement.
Every major story explains what the evidence does not prove, plus important uncertainty and conflicts.
Each Tuesday, we focus on the most worthwhile evidence in a clear five-minute read.
The signal, without the hype
Free, every Tuesday. Confirm once and you’re in.